Skip to main content
. Author manuscript; available in PMC: 2024 Mar 1.
Published in final edited form as: Clin Cancer Res. 2023 Sep 1;29(17):3329–3339. doi: 10.1158/1078-0432.CCR-23-0709

Figure 3: Genomic studies of correlative samples.

Figure 3:

(A) Oncoprint showing the variant genetic alterations identified in the study cases. (B) Calculated tumor fraction fold change detected in cfDNA over time. (C) Comparison of fusion-negative and fusion-positive samples for calculated coverage of known PAX3-FOXO1 binding sites.